Fulcrum Therapeutics (NASDAQ:FULC) Rating Lowered to “Hold” at Cantor Fitzgerald

Fulcrum Therapeutics (NASDAQ:FULC) was downgraded by research analysts at Cantor Fitzgerald from a “strong-buy” rating to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.

FULC has been the subject of a number of other research reports. Wall Street Zen raised shares of Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 2nd. Jefferies Financial Group set a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Tuesday. Leerink Partners downgraded shares of Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 target price for the company. in a research report on Tuesday. HC Wainwright downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 target price for the company. in a research report on Tuesday. Finally, Stifel Nicolaus downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 target price for the company. in a research report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $8.20.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ FULC opened at $3.14 on Tuesday. The company has a 50 day simple moving average of $7.23 and a 200 day simple moving average of $9.22. The firm has a market cap of $209.22 million, a PE ratio of -2.73 and a beta of 2.93. Fulcrum Therapeutics has a 1 year low of $2.83 and a 1 year high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.06. As a group, research analysts anticipate that Fulcrum Therapeutics will post -1.16 earnings per share for the current fiscal year.

Institutional Trading of Fulcrum Therapeutics

Large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Fulcrum Therapeutics during the 4th quarter worth approximately $30,000. Quarry LP acquired a new stake in shares of Fulcrum Therapeutics during the 3rd quarter worth approximately $35,000. Meeder Asset Management Inc. acquired a new stake in shares of Fulcrum Therapeutics during the 4th quarter worth approximately $39,000. Summit Securities Group LLC acquired a new stake in shares of Fulcrum Therapeutics during the 1st quarter worth approximately $53,000. Finally, Russell Investments Group Ltd. grew its position in shares of Fulcrum Therapeutics by 4,209.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock worth $64,000 after buying an additional 9,092 shares during the period. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics News Roundup

Here are the key news stories impacting Fulcrum Therapeutics this week:

• Positive Sentiment: Fulcrum said it will explore strategic alternatives, including a potential sale or merger, which could unlock value if a transaction emerges.
• Neutral Sentiment: Leerink Partners reaffirmed a market perform rating and set a $4 price target, while Stifel kept a hold rating with a $3 target.
• Negative Sentiment: The company discontinued pociredir after FDA concerns over cancer risk, removing its lead program and raising doubts about Fulcrum’s long-term pipeline. Article Title
• Negative Sentiment: Multiple law firms launched investigations into possible securities law violations following the stock’s collapse, adding legal overhang. Article Title

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small?molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.